The FDA is trying to be proactive in regulating device clinical trials through Bioresearch Monitoring (BiMo) audits, Tim Ulatowski, director of compliance for CDRH, said. The agency is doing more BiMo audits earlier in clinical trials, to try to catch things at the “front end,” he added, speaking at the recent FDAnews Medical Device Quality Conference.
